ABSTRACT
BCL-2 is an antiapoptotic protein that plays a critical role acute and chronic leukemias. Venetoclax is an orally selective BCL-2 inhibitor and BH3 mimetic approved in chronic lymphocytic leukemia and in combination with low dose cytarabine or hypomethylating agent in acute myeloid leukemia for the treatment of patients unfit for intensive chemotherapy. This article reviews the biology of BCL-2, focusing on its relationship to the myeloid microenvironment, and discusses the rationale for BCL-2 inhibition in myelodysplastic syndrome (MDS). Clinical trials testing venetoclax in MDS patients are under way. Potential biomarkers for clinical response to BCL-2 inhibition are discussed. Therapeutic opportunities for venetoclax in the therapeutic landscape of MDS are explored.
Subject(s)
Bridged Bicyclo Compounds, Heterocyclic/therapeutic use , Myelodysplastic Syndromes/drug therapy , Sulfonamides/therapeutic use , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Apoptosis/genetics , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Clinical Studies as Topic , Disease Management , Disease Models, Animal , Disease Susceptibility , Drug Evaluation, Preclinical , Humans , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/etiology , Mitochondria/drug effects , Mitochondria/genetics , Mitochondria/metabolism , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/etiology , Myelodysplastic Syndromes/metabolism , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , Sulfonamides/pharmacology , Treatment OutcomeABSTRACT
Bone marrow stromal cells from patients with myelodysplastic syndrome (MDS) display a senescence phenotype, but the underlying mechanism has not been elucidated. Pro-inflammatory signaling within the malignant clone and the bone marrow microenvironment has been identified as a key pathogenetic driver of MDS. Our study revealed that S100A9 is highly-expressed in lower-risk MDS. Moreover, normal primary mesenchymal stromal cells (MSCs) and the human stromal cell line HS-27a co-cultured with lower-risk MDS bone marrow mononuclear cells acquired a senescence phenotype. Exogenous supplemented S100A9 also induced cellular senescence in MSCs and HS-27a cells. Importantly, Toll-like receptor 4 (TLR4) inhibition or knockdown attenuated the cellular senescence induced by S100A9. Furthermore, we showed that S100A9 induces NLRP3 inflammasome formation, and IL-1ß secretion; findings in samples from MDS patients further confirmed these thoughts. Moreover, ROS and IL-1ß inhibition suppressed the cellular senescence induced by S100A9, whereas NLRP3 overexpression and exogenous IL-1ß supplementation induces cellular senescence. Our study demonstrated that S100A9 promotes cellular senescence of bone marrow stromal cells via TLR4, NLRP3 inflammasome formation, and IL-1ß secretion for its effects. Our findings deepen the understanding of the molecular mechanisms involved in MDS reprogramming of MSCs and indicated the essential role of S100A9 in tumor-environment interactions in bone marrow.
Subject(s)
Calgranulin B/metabolism , Cellular Senescence/physiology , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Case-Control Studies , Cell Line , Cells, Cultured , Cellular Reprogramming/physiology , Female , Humans , Inflammasomes/metabolism , Interleukin-1beta/metabolism , Male , Middle Aged , Myelodysplastic Syndromes/etiology , Myelodysplastic Syndromes/metabolism , Myelodysplastic Syndromes/pathology , NLR Family, Pyrin Domain-Containing 3 Protein/genetics , Reactive Oxygen Species/metabolism , Signal Transduction , Stem Cell Niche/physiology , Toll-Like Receptor 4/metabolism , Up-Regulation , Young AdultABSTRACT
In acute myeloid leukemia (AML), myelodysplasia-related changes contribute to a poor prognosis. This retrospective, propensity score-matched study analyzed 108 newly diagnosed AML patients with features of myelodysplasia syndrome (MDS) (aged 14-60 years) from 2014 to 2018, who received either idarubicin and cytarabine (IA) or decitabine, idarubicin and cytarabine (DAC+IA), and compared efficacy and toxicity between the two regimens. After propensity score matching, there were 54 patients in each group. The rate of complete remission (CR) was higher in the DAC+IA group than in the IA group (85.2% vs 68.5%, P = .040) after the first course, and toxicities were comparable in both groups. Multivariate analysis indicated that the combination with DAC was independent factor for CR rate after the first induction therapy (OR = 2.978, 95% CI:1.090-8.137, P = .033). Subgroup analysis showed a CR advantage for DAC+IA (vs IA) for patients of intermediate-high risk status according to National Comprehensive Cancer Network prognostic stratification. In conclusion, DAC+IA is therefore offered as a new induction choice for newly diagnosed AML patients with features of MDS, aged <60 years old, especially in intermediate-high risk status.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Myeloid, Acute/diagnosis , Leukemia, Myeloid, Acute/drug therapy , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/drug therapy , Adolescent , Adult , Age Factors , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Biomarkers , Decitabine/administration & dosage , Diagnosis, Differential , Disease Management , Disease Susceptibility , Female , Follow-Up Studies , Humans , Induction Chemotherapy , Leukemia, Myeloid, Acute/etiology , Leukemia, Myeloid, Acute/mortality , Male , Middle Aged , Myelodysplastic Syndromes/etiology , Myelodysplastic Syndromes/mortality , Prognosis , Propensity Score , Retreatment , Retrospective Studies , Treatment Outcome , Young AdultABSTRACT
Excess iron can be extremely toxic for the body and may cause organ damage in the absence of iron chelation therapy. Preclinical studies on the role of free iron on bone marrow function have shown that iron toxicity leads to the accumulation of reactive oxygen species, affects the expression of genes coding for proteins that regulate hematopoiesis, and disrupts hematopoiesis. These effects could be partially attenuated by iron-chelation treatment with deferasirox, suggesting iron toxicity may have a negative impact on the hematopoietic microenvironment. Iron toxicity is of concern in transfusion-dependent patients. Importantly, iron chelation with deferasirox can cause the loss of transfusion dependency and may induce hematological responses, although the mechanisms through which deferasirox exerts this action are currently unknown. This review will focus on the possible mechanisms of toxicity of free iron at the bone marrow level and in the bone marrow microenvironment.
Subject(s)
Bone Marrow/metabolism , Disease Susceptibility , Iron/metabolism , Anemia, Aplastic/complications , Anemia, Aplastic/etiology , Anemia, Aplastic/metabolism , Anemia, Aplastic/therapy , Animals , Bone Marrow Cells/metabolism , Cellular Microenvironment , Hematopoietic Stem Cells/metabolism , Humans , Iron Chelating Agents/therapeutic use , Iron Overload/drug therapy , Iron Overload/etiology , Iron Overload/metabolism , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/etiology , Myelodysplastic Syndromes/metabolism , Myelodysplastic Syndromes/therapy , Primary Myelofibrosis/complications , Primary Myelofibrosis/etiology , Primary Myelofibrosis/metabolism , Primary Myelofibrosis/therapyABSTRACT
Diamond-Blackfan anemia (DBA) is a congenital red cell aplasia arising from ribosomal protein (RP) defects. Affected patients present with neonatal anemia, occasional dysmorphism, and cancer predisposition. An anemic newborn was diagnosed with DBA due to RPL5 mutation (c.473_474del, p.K158SfsX26). Refractory anemia required regular transfusions and iron chelation therapy. Pancytopenia occurred at age 16 years. Bone-marrow studies showed myelodysplasia, erythroblastosis, and clonal evolution of del(20)(q11.2q13.3). Severe anemia required transfusions. Del(20q), including the L3MBTL1 gene, is reported to be relevant to the hematological phenotype of Shwachman-Diamond syndrome. A combined defect of RPL5 and L3MBTL1 may contribute to the aberrant erythropoiesis in the present case.
Subject(s)
Anemia, Diamond-Blackfan/blood , Anemia, Diamond-Blackfan/complications , Chromosome Deletion , Chromosomes, Human, Pair 20/genetics , Clonal Evolution/genetics , Erythroblastosis, Fetal/blood , Erythroblastosis, Fetal/etiology , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/etiology , Myelodysplastic Syndromes/genetics , Adolescent , Anemia, Diamond-Blackfan/therapy , Blood Transfusion , Chromosomal Proteins, Non-Histone/genetics , Disease Progression , Erythroblastosis, Fetal/genetics , Erythropoiesis/genetics , Female , Hematopoietic Stem Cell Transplantation , Humans , Myelodysplastic Syndromes/therapy , Pancytopenia/etiology , Repressor Proteins , Ribosomal Proteins/genetics , Severity of Illness Index , Tumor Suppressor ProteinsABSTRACT
DISEASE OVERVIEW: The myelodysplastic (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older male and in individuals with prior exposure to cytotoxic therapy. DIAGNOSIS: Diagnosis of MDS is based on morphological evidence of dysplasia upon visual examination of a bone marrow aspirate and biopsy. Information obtained from additional studies such as karyotype, flow cytometry or molecular genetics is complementary but not diagnostic. RISK-STRATIFICATION: Prognosis of patients with MDS can be calculated using a number of scoring systems. In general, all these scoring systems include analysis of peripheral cytopenias, percentage of blasts in the bone marrow and cytogenetic characteristics. The most commonly used system is the International Prognostic Scoring System (IPSS). IPSS is likely to be replaced by a new revised score (IPSS-R) and by the incorporation of new molecular markers recently described. RISK-ADAPTED THERAPY: Therapy is selected based on risk, transfusion needs, percent of bone marrow blasts and more recently cytogenetic profile. Goals of therapy are different in lower risk patients than in higher risk. In lower risk, the goal is to decrease transfusion needs and transformation to higher risk disease or AML, as well as to improve survival. In higher risk, the goal is to prolong survival. Current available therapies include growth factor support, lenalidomide, hypomethylating agents, intensive chemotherapy, and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia, and a chromosome 5 alteration. 5-Azacitidine and decitabine have activity in higher risk MDS. 5-Azacitidine has been shown to improve survival in higher risk MDS. A number of new molecular lesions have been described in MDS that may serve as new therapeutic targets or aid in the selection of currently available agents. Additional supportive care measures may include the use of prophylactic antibiotics and iron chelation. MANAGEMENT OF PROGRESSIVE OR REFRACTORY DISEASE: There are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options include cytarabine based therapy, transplantation and participation on a clinical trial.
Subject(s)
Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/therapy , Humans , Myelodysplastic Syndromes/etiology , PrognosisABSTRACT
BACKGROUND: Benzene at high concentrations is known to cause acute myeloid leukemia (AML), but its relationship with other lymphohematopoietic (LH) cancers remains uncertain, particularly at low concentrations. In this pooled analysis, we examined the risk of five LH cancers relative to lower levels of benzene exposure in petroleum workers. METHODS: We updated three nested case-control studies from Australia, Canada, and the United Kingdom with new incident LH cancers among petroleum distribution workers through December 31, 2006, and pooled 370 potential case subjects and 1587 matched LH cancer-free control subjects. Quantitative benzene exposure in parts per million (ppm) was blindly reconstructed using historical monitoring data, and exposure certainty was scored as high, medium, or low. Two hematopathologists assigned diagnoses and scored the certainty of diagnosis as high, medium, or low. Dose-response relationships were examined for five LH cancers, including the three most common leukemia cell-types (AML, chronic myeloid leukemia [CML], and chronic lymphoid leukemia [CLL]) and two myeloid tumors (myelodysplastic syndrome [MDS] and myeloproliferative disease [MPD]). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression, controlling for age, sex, and time period. RESULTS: Cumulative benzene exposure showed a monotonic dose-response relationship with MDS (highest vs lowest tertile, >2.93 vs ≤0.348 ppm-years, OR = 4.33, 95% CI = 1.31 to 14.3). For peak benezene exposures (>3 ppm), the risk of MDS was increased in high and medium certainty diagnoses (peak exposure vs no peak exposure, OR = 6.32, 95% CI = 1.32 to 30.2) and in workers having the highest exposure certainty (peak exposure vs no peak exposure, OR = 5.74, 95% CI = 1.05 to 31.2). There was little evidence of dose-response relationships for AML, CLL, CML, or MPD. CONCLUSIONS: Relatively low-level exposure to benzene experienced by petroleum distribution workers was associated with an increased risk of MDS, but not AML, suggesting that MDS may be the more relevant health risk for lower exposures.
Subject(s)
Benzene/toxicity , Extraction and Processing Industry , Myelodysplastic Syndromes/epidemiology , Myelodysplastic Syndromes/etiology , Occupational Diseases/epidemiology , Occupational Diseases/etiology , Occupational Exposure/adverse effects , Petroleum , Adult , Australia/epidemiology , Canada/epidemiology , Case-Control Studies , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology , Leukemia, Lymphocytic, Chronic, B-Cell/etiology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/epidemiology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/etiology , Leukemia, Myeloid, Acute/epidemiology , Leukemia, Myeloid, Acute/etiology , Logistic Models , Male , Middle Aged , Myelodysplastic Syndromes/chemically induced , Myelodysplastic Syndromes/diagnosis , Myeloproliferative Disorders/epidemiology , Myeloproliferative Disorders/etiology , Occupational Diseases/chemically induced , Odds Ratio , United Kingdom/epidemiologyABSTRACT
BACKGROUND: The etiology of myelodysplastic syndromes (MDS) is largely unknown. Exposure to cigarette smoke (CS) is reported to be associated with MDS risk. There is inconsistent evidence that deficiency of NAD(P)H-quinone: oxidoreductase 1 (NQO1) increases the risk of MDS. Earlier we had shown that CS induces toxicity only in marginal vitamin C-deficient guinea pigs but not in vitamin C-sufficient ones. We therefore considered that NQO1 deficiency along with marginal vitamin C deficiency might produce MDS in CS-exposed guinea pigs. METHODOLOGY AND PRINCIPAL FINDINGS: Here we show that CS exposure for 21 days produces MDS in guinea pigs having deficiency of NQO1 (fed 3 mg dicoumarol/day) conjoint with marginal vitamin C deficiency (fed 0.5 mg vitamin C/day). As evidenced by morphology, histology and cytogenetics, MDS produced in the guinea pigs falls in the category of refractory cytopenia with unilineage dysplasia (RCUD): refractory anemia; refractory thrombocytopenia that is associated with ring sideroblasts, micromegakaryocytes, myeloid hyperplasia and aneuploidy. MDS is accompanied by increased CD34(+) cells and oxidative stress as shown by the formation of protein carbonyls and 8-oxodeoxyguanosine. Apoptosis precedes MDS but disappears later with marked decrease in the p53 protein. MDS produced in the guinea pigs are irreversible. MDS and all the aforesaid pathophysiological events do not occur in vitamin C-sufficient guinea pigs. However, after the onset of MDS vitamin C becomes ineffective. CONCLUSIONS AND SIGNIFICANCE: CS exposure causes MDS in guinea pigs having deficiency of NQO1 conjoint with marginal vitamin C deficiency. The syndromes are not produced in singular deficiency of NQO1 or marginal vitamin C deficiency. Our results suggest that human smokers having NQO1 deficiency combined with marginal vitamin C deficiency are likely to be at high risk for developing MDS and that intake of a moderately large dose of vitamin C would prevent MDS.
Subject(s)
Ascorbic Acid Deficiency/physiopathology , Myelodysplastic Syndromes/chemically induced , Myelodysplastic Syndromes/etiology , NAD(P)H Dehydrogenase (Quinone)/deficiency , Tobacco Smoke Pollution/adverse effects , Animals , Apoptosis/drug effects , Ascorbic Acid/blood , Ascorbic Acid/metabolism , Bone Marrow/metabolism , Flow Cytometry , Guinea Pigs , Humans , In Situ Nick-End Labeling , Male , NAD(P)H Dehydrogenase (Quinone)/metabolism , Reactive Oxygen Species/metabolismABSTRACT
BACKGROUND: We report a retrospective study of 452 patients with lymphoma from 1991 to 2006, with 274 men and 178 women, median age of 50 years (range, 16-76 years). PATIENTS AND METHODS: There were 85 patients with Hodgkin lymphoma (HL) and 367 with non-Hodgkin lymphoma (NHL). Eleven patients received a second autologous transplantation for progressive lymphoma, and another 4 received a second allogeneic transplantation for myelodysplastic syndrome (MDS). Twenty-seven patients had skin biopsies, and 2 patients had gastrointestinal biopsies consistent with graft-versus-host disease (GVHD), and 11 patients developed severe engraftment syndrome (ES), as defined by noninfectious fever and skin rash with or without pulmonary infiltrates requiring systemic steroids. RESULTS: The median follow-up of the patients was 6.2 years, and median overall survival was 5.3 years. Twenty-four patients (5.3%) developed MDS with median time of onset of 4.2 years (range, 8 months to 7.5 years). An additional 5 patients developed clonal karyotypic abnormalities in the bone marrow without clinical MDS. Actuarial probabilities of developing MDS at 5 and 8 years after transplantation were 5% and 15%, respectively. CONCLUSION: The incidences of MDS are similar in HL and NHL. Multivariate analysis revealed older age, occurrence of ES/GVHD, and longer intervals between the initial diagnoses to transplantation as independent factors. It is conceivable that perturbation to the host immunity caused by either previous chemotherapy or conditioning regimens in the elderly might play a role in the development of MDS after autologous transplantation.
Subject(s)
Graft vs Host Disease/drug therapy , Hodgkin Disease/therapy , Lymphoma, Non-Hodgkin/therapy , Myelodysplastic Syndromes/etiology , Myelodysplastic Syndromes/therapy , Aged , Biological Therapy/adverse effects , Bone Marrow/pathology , Female , Graft vs Host Disease/etiology , Graft vs Host Disease/mortality , Hematopoietic Stem Cell Transplantation/adverse effects , Hodgkin Disease/complications , Hodgkin Disease/drug therapy , Humans , Immune System Diseases/complications , Immune System Diseases/drug therapy , Incidence , Lymphoma/complications , Lymphoma/drug therapy , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/pathology , Male , Myelodysplastic Syndromes/drug therapy , Retrospective Studies , Stem Cell Transplantation/adverse effects , Syndrome , Transplantation, Autologous/adverse effects , Transplantation, Homologous/adverse effectsABSTRACT
The myelodysplastic syndromes (MDS) are clonal bone marrow disorders that lead to underproduction of normal blood cells. The consequent cytopenias result in infections and bleeding complications. MDS transform to acute myeloid leukemia in one-third of patients. The number of diagnoses has exploded in the past decade as a result of increased recognition and understanding of the disease and the aging of the population. New therapies can extend life. MDS are now considered the most common form of leukemia, and in some cases deserve immediate intervention. This review describes common presentations of MDS, optimal diagnostic approaches, and therapies for lower-and higher-risk disease.
Subject(s)
Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/therapy , Age Distribution , Anemia/etiology , Anti-Bacterial Agents/therapeutic use , Blood Cell Count , Chelation Therapy , Erythrocyte Transfusion , Erythropoietin/therapeutic use , Hematinics/therapeutic use , Humans , Myelodysplastic Syndromes/classification , Myelodysplastic Syndromes/etiology , Recombinant ProteinsABSTRACT
The objective of the study was to investigate factors related to the occurrence of myelodysplatic syndromes (MDS) in the population of Belgrade (Serbia Montenegro). The case-control study was conducted during the period 2000-2003. The study group consisted of 80 newly diagnosed MDS patients and 160 sex- and age-matched hospital controls with nonmalignant and noninfectious diseases. The disease categories in the control group were circulatory (51 patients, 32%), gastrointestinal (53 patients, 33%), and ophthalmological (56 patients, 35%) disorders. Conditional univariate and multivariate logistic regression analyses were applied. Multivariate analysis showed the following factors to be significantly related to MDS: exposure to chemicals (OR = 10.8, 95%CI 3.2-36.2, p = 0.0001), viral upper respiratory tract infections (twice a year or more, OR = 5.8, 95%CI 2.5-13.6, p = 0.0001), exposure to insecticides, pesticides and herbicides (OR = 5.2, 95%CI 1.8-15.1, p = 0.003), coffee (OR = 5.1, 95%CI 1.9-13.7, p = 0.001), and alcohol consumption (OR = 2.2, 95%CI 1.1-4.6, p = 0.033). The findings support the hypotheses that exposure to chemical agents, pesticides, insecticides, and herbicides, certain lifestyle factors (alcohol and coffee consumption), and frequent viral infections may be involved in the etiology of MDS, but these results should be confirmed by further investigations.
Subject(s)
Alcohol Drinking/adverse effects , Environmental Exposure/adverse effects , Myelodysplastic Syndromes/etiology , Respiratory Tract Diseases/complications , Virus Diseases/complications , Adult , Aged , Aged, 80 and over , Case-Control Studies , Coffee/adverse effects , Female , Herbicides/adverse effects , Humans , Male , Middle Aged , Myelodysplastic Syndromes/epidemiology , Retrospective Studies , Risk Factors , YugoslaviaABSTRACT
We report a 36-year-old male with myeloid/natural killer (NK)-cell precursor acute leukaemia with a complex aberrant karyotype, who was treated according to an acute-myeloid-leukaemia (AML) treatment protocol (idarubicine, cytarabine, and etoposide) followed by high-dose cytarabine consolidation and achieved complete remission. He underwent allogeneic matched unrelated donor (MUD) peripheral blood stem-cell transplantation (PBSCT) and remained in remission throughout his remaining life. Seven months posttransplantation, a myelodysplastic syndrome (MDS) with (20q-) of donor origin was diagnosed causing severe thrombocytopenia and finally leading to infection and death. This patient represents one of the few cases published achieving remission for a significant period of time after being diagnosed with myeloid/NK-cell precursor acute leukaemia, a very rare malignant disease. We conclude, despite the fatal outcome due to infection, that allogeneic PBSCT is a therapeutic option for patients with this entity. In addition, the development of a myelodysplastic syndrome of donor origin is extremely rare and only very few cases are published worldwide.
Subject(s)
Killer Cells, Natural/pathology , Leukemia, Myeloid/pathology , Leukemia, Myeloid/therapy , Leukemia, Prolymphocytic, T-Cell/pathology , Myelodysplastic Syndromes/etiology , Peripheral Blood Stem Cell Transplantation/methods , Acute Disease , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Disease-Free Survival , Fatal Outcome , Humans , Infections , Leukemia, Prolymphocytic, T-Cell/therapy , Male , Remission Induction/methods , Thrombocytopenia , Tissue Donors , Transplantation, Homologous , Treatment OutcomeABSTRACT
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematological diseases deriving from a clonally expanded precursor bone marrow cell. MDS are characterized by ineffective hematopoiesis, peripheral cytopenias of various degrees and increased risk for transformation into acute myeloid leukemia. The incidence is highest in elderly people. Diagnosis is based on morphology, exclusion of reactive causes of dyshematopoiesis and cytogenetics/FISH. Allogeneic stem cell transplantation, the only curative therapy so far, is not feasible for most of the patients. Other therapeutic options include supportive therapy such as blood transfusions and antibiotics, hematopoietic growth factors (rHuEPO, G-CSF), immunomodulating agents and chemotherapy. It is important to install iron chelation therapy in cases with long term transfusion dependency.
Subject(s)
Myelodysplastic Syndromes/diagnosis , Aged , Bone Marrow/pathology , Cell Transformation, Neoplastic/pathology , Diagnosis, Differential , Humans , Leukemia, Myeloid/classification , Leukemia, Myeloid/diagnosis , Leukemia, Myeloid/etiology , Leukemia, Myeloid/therapy , Myelodysplastic Syndromes/classification , Myelodysplastic Syndromes/etiology , Myelodysplastic Syndromes/therapy , Prognosis , Risk Factors , World Health OrganizationABSTRACT
Therapy-related myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML) are serious complications of chemotherapy and radiotherapy for cancer. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may be associated with an increased incidence of these complications. The frequency of t-MDS/AML after ASCT for breast cancer is uncertain. We reviewed our database of 379 consecutive breast cancer ASCT patients treated with alkylator-based chemotherapy, followed for a median of 1.52 years (range 0-8.97), with a median survival of 6.16 years. Three patients have developed tMDS/AML. The probability of developing this complication at 5 years is 0.032 in our series. We have used pathologic, cytogenetic and molecular methods to evaluate which portions of therapy may have predisposed to the development of this complication. Cytogenetic abnormalities were not found in the stem cell harvests of these patients by metaphase analysis or by fluorescence in situ hybridization (FISH). One patient demonstrated a clonal X chromosome inactivation pattern in her stem cell harvest, indicating pre-transplant chemotherapy may have been responsible for the development of her leukemia. As two of our patients developed this complication at greater than 4 years post-transplant, the number of cases may increase with longer follow-up. While the incidence appears to be low, further prospective and retrospective analysis will be necessary to determine which portions of therapy predispose to the development of t-MDS/AML in patients undergoing ASCT for treatment of breast cancer.
Subject(s)
Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Leukemia, Myeloid/etiology , Myelodysplastic Syndromes/etiology , Neoplasms, Second Primary/etiology , Acute Disease , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chromosome Aberrations , Cyclophosphamide/therapeutic use , DNA, Neoplasm/metabolism , Doxorubicin/therapeutic use , Female , Fluorouracil/therapeutic use , Humans , In Situ Hybridization, Fluorescence , Karyotyping , Middle Aged , Neoplasms, Second Primary/pathology , Predictive Value of Tests , Receptors, Androgen/genetics , Receptors, Androgen/metabolism , Retrospective Studies , Survival Rate , Time Factors , Transplantation Conditioning/adverse effects , Transplantation, AutologousABSTRACT
Anemia should not be accepted as an inevitable consequence of aging. A cause is found in approximately 80 percent of elderly patients. The most common causes of anemia in the elderly are chronic disease and iron deficiency. Vitamin B12 deficiency, folate deficiency, gastrointestinal bleeding and myelodysplastic syndrome are among other causes of anemia in the elderly. Serum ferritin is the most useful test to differentiate iron deficiency anemia from anemia of chronic disease. Not all cases of vitamin B12 deficiency can be identified by low serum levels. The serum methylmalonic acid level may be useful for diagnosis of vitamin B12 deficiency. Vitamin B12 deficiency is effectively treated with oral vitamin B12 supplementation. Folate deficiency is treated with 1 mg of folic acid daily.
Subject(s)
Anemia , Aged , Anemia/diagnosis , Anemia/etiology , Anemia/therapy , Anemia, Hypochromic/diagnosis , Anemia, Hypochromic/etiology , Anemia, Hypochromic/therapy , Diagnosis, Differential , Folic Acid Deficiency/diagnosis , Folic Acid Deficiency/etiology , Folic Acid Deficiency/therapy , Humans , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/etiology , Myelodysplastic Syndromes/therapy , Vitamin B 12 Deficiency/diagnosis , Vitamin B 12 Deficiency/etiology , Vitamin B 12 Deficiency/therapyABSTRACT
We determined prospectively the incidence of chromosomal abnormalities in patients with high-risk breast cancer (HRBC) after high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT), and correlated the cytogenetic abnormalities with the development of post-transplant myelodysplastic syndrome or acute myeloid leukemia (MDS/AML). From 1990 to 1999, 229 women with HRBC underwent ASCT. Cytogenetic analysis of bone marrow (BM) cells was performed 12-59 months after ASCT in 60 consecutive women uniformly treated with six courses of FAC/FEC followed by HDCT and ASCT. With a median follow-up of 36 months after ASCT, there were no cases of MDS/AML among the 229 patients. In the selected cohort of 60 patients, three (5%) showed clonal chromosomal abnormalities (two single trisomy X and one t(1;6)), whereas two additional patients showed non-clonal reciprocal translocations. Two of the patients with clonal aberrations had blood cytopenias as well as subtle dysplastic pictures in BM which were not classifiable as MDS according to the FAB criteria. Similar dysplastic features were also observed in four patients with normal karyotypes. All cytogenetic aberrations were transient and disappeared, except a +X detected by FISH in a residual cell population in one of the patients. Retrospective cytogenetic and FISH studies of samples obtained after six cycles of FAC/FEC and before transplant demonstrated no chromosomal abnormalities in any of the five patients with post-ASCT karyotypic changes. Early changes in karyotype detected in breast cancer patients following ASCT are transient and do not correlate with or predict development of MDS/AML. As these aberrations were not present before ASCT, they may be related to the HDCT regimen or transplant procedure rather than to the prior adjuvant therapy. Our results suggest that ASCT may be less likely to cause MDS or AML in breast cancer patients as compared to other malignancies. Bone Marrow Transplantation (2000) 25, 1203-1208.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/genetics , Breast Neoplasms/therapy , Chromosome Aberrations , Hematopoietic Stem Cell Transplantation/adverse effects , Leukemia/etiology , Myelodysplastic Syndromes/etiology , Neoplasms, Second Primary/etiology , Adult , Bone Marrow/pathology , Breast Neoplasms/pathology , Chemotherapy, Adjuvant , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Epirubicin/administration & dosage , Female , Fluorouracil/administration & dosage , Humans , Middle Aged , Neoplasm Staging , Postmenopause , Predictive Value of Tests , Premenopause , Transplantation, AutologousABSTRACT
We report two cases of secondary myelodysplastic syndrome (SMDS) which followed successful treatment of a primary malignancy with high-dose chemotherapy supported by reinfusion of autologous stem cells. The SMDS was diagnosed 24 months and 40 months, respectively, following autografting. Both patients lived for 7 months after the diagnosis of SMDS. Our cases support the view that there is an increased risk of SMDS/acute leukemia following autologous marrow transplantation.
Subject(s)
Bone Marrow Transplantation/adverse effects , Myelodysplastic Syndromes/etiology , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bleomycin/administration & dosage , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Dose-Response Relationship, Drug , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Humans , Leucovorin/administration & dosage , Lymphoma/drug therapy , Lymphoma/therapy , Male , Methotrexate/administration & dosage , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/epidemiology , Prednisone/administration & dosage , Procarbazine/administration & dosage , Rectal Neoplasms/drug therapy , Rectal Neoplasms/therapy , Risk Factors , Seminoma/drug therapy , Seminoma/therapy , Testicular Neoplasms/drug therapy , Testicular Neoplasms/therapy , Transplantation, Autologous , Vincristine/administration & dosageABSTRACT
The increasing incidence of therapy-related leukemia and myelodysplastic syndrome reflects (1) a longer period at risk resulting from successful treatment of solid tumors; (2) more intensive treatment regimens combining high-dose chemotherapy and irradiation; (3) broader utilization of adjuvant chemoirradiation in melanoma, colon, lung, breast, and head and neck cancers; and (4) environmental pollution and widespread exposure to chemicals and carcinogens in industrialized nations. The availability of novel therapies, including growth factors, has increased the referral of these patients to comprehensive cancer centers, partially explaining the increased awareness of the entity.
Subject(s)
Leukemia, Myeloid/therapy , Myelodysplastic Syndromes/therapy , Neoplasms, Second Primary/therapy , Acute Disease , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Bone Marrow Transplantation , Chromosome Aberrations , Clinical Trials as Topic , Combined Modality Therapy , Drug Evaluation , Humans , Immunologic Factors/therapeutic use , Incidence , Interferons/therapeutic use , Leukemia, Myeloid/epidemiology , Leukemia, Myeloid/etiology , Leukemia, Myeloid/pathology , Leukemia, Radiation-Induced , Myelodysplastic Syndromes/epidemiology , Myelodysplastic Syndromes/etiology , Myelodysplastic Syndromes/pathology , Neoplasms, Second Primary/epidemiology , Neoplasms, Second Primary/etiology , Neoplasms, Second Primary/pathology , Remission Induction , Transplantation, HomologousABSTRACT
A rare case of hemolytic anemia complicated with Behçet's disease and myelodysplastic syndrome (MDS) is described. A 41-year old woman suffering from hemolytic anemia was admitted in July of 1988 with right lower abdominal pain and a high fever. Her anemia was first pointed out in 1962 (at age 15), and diagnosed as hemolytic anemia in 1977 by a full hematological examination showing erythro-hyperplasia in bone marrow, Coomb's test was negative and corticosteroid therapy failed to improve her anemia. She had also been suffering from recurrent stomatitis and genital ulcer since the delivery of her first baby in July, 1972. Barium enema was performed and revealed a simple deep ulcer at the terminal ileum. Bone marrow examination showed morphological abnormalities of granulocytic and erythrocytic series. We thereby diagnosed her illness as incomplete Behçet's disease and MDS associated with hemolytic anemia. She was treated by ubenimex, blood transfusion and intravenous alimentation with discontinuing oral intake, and there was a satisfactory improvement in pancytopenia and ulcer.